G. Tortora

Molecular Biology · Nature · 2000–2019

A researcher in the Science corpus: 14 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 116 citations into it

Whom G. Tortora trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Fortunato Ciardiello

Papers from G. Tortora's perspective

Ordered by how strongly the researchers G. Tortora trusts endorse each paper. Same corpus, a different order for every researcher.

1. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. (Cancer Research)
2. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. (Annals of Oncology)
3. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. (Journal of Clinical Oncology)
4. Tumor angiogenesis (Advances in Cancer Research)
5. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. (New England Journal of Medicine)
6. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. (New England Journal of Medicine)
7. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. (Clinical Cancer Research)
8. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. (Clinical Cancer Research)
9. Protein Modules and Signaling Networks
10. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. (Journal of Clinical Oncology)

Their papers

• Whole genomes redefine the mutational landscape of pancreatic cancer (2015) — 2,461 citations
• Genomic analyses identify molecular subtypes of pancreatic cancer (2016) — 3,221 citations
• Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas (2013) — 628 citations
• Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer (2019) — 1,834 citations
• Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy (2018) — 670 citations
• A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2018) — 704 citations
• Whole-genome landscape of pancreatic neuroendocrine tumours (2017) — 870 citations
• nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. (2015) — 625 citations
• Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes (2012) — 1,987 citations
• EGFR antagonists in cancer treatment. (2008) — 2,077 citations
• ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. (2002) — 632 citations
• A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. (2001) — 1,039 citations
• Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. (2001) — 662 citations
• Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. (2000) — 998 citations